Company profilePharmaceutical#86 of 1,318 in Pakistan10 DRAP alerts

The Schazoo Pharmaceutical Laboratories (Pvt.) Ltd.

Pharmaceutical company · 181 brands · 198 molecules

Ranked #55 of 207 companies in Quinolone Antibacterials

181 registered products 53 pharmaceutical brands 198 distinct molecules 10 DRAP alerts

Company overview

181
registered products
53
pharmaceutical brands
198
distinct molecules
12
therapeutic classes
10
DRAP alerts

The Schazoo Pharmaceutical Laboratories (Pvt.) Ltd. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 181 product registrations across 198 distinct molecules. It is the 86th largest registrant in Pakistan by product count, and ranks 55th of 207 in Quinolone Antibacterials. Its portfolio is concentrated in Quinolone Antibacterials and Antiglaucoma Preparations And Miotics. DRAP has issued 28 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by The

122 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Psychostimulants, Nootropic & Neurotonic 3
Antiinflammatory And Antirheumatic Products 2

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

101
ceilings with an approval date
1
not revised in 2+ years
2024
oldest approval year
20241
2026100
Longest without revision

Top molecules by brand count

Eye6 brands
Paracetamol6 brands
Quetiapine5 brands
Levofloxacin5 brands
Ondansetron5 brands
Levamisole5 brands
Lamotrigine5 brands
Timolol4 brands

Therapeutic classes

Quinolone Antibacterials · 3Antiglaucoma Preparations And Miotics · 3Antiinflammatory Agents And Antiinfectives In Combination · 2Antiepileptics · 2Other Nasal Preparations · 2Decongestants And Antiallergics · 2Psycholeptics; Antipsychotics, Anxiolytics, Hypnotics And Sedatives · 2Opioids · 1Mydriatics And Cycloplegics · 1Cancer · 1Endocrine Hormone Therapy · 1Gastro · 1

Conditions treated

Oncology · 1Colic/Constipation · 1Neuropathic Pain/Epilepsy/Convulsion · 1Oral Agents · 1Pain Killers · 1Glaucoma/Mydriasis · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official164 products · Rs 16.71 – Rs 32,433.03
DVAGO7 products · Rs 97 – Rs 660
Servaid10 products · Rs 140 – Rs 6,000
Median across source: Rs 347.41

Regulatory record

10 alerts in the DRAP feed we track.

Advisory to Therapeutic Goods Manufacturers: Measures to Prevent DEG/EG Contamination in O
2025-10-16
ADVISORY TO THERAPEUTIC GOODS MANUFACTURERS: MEASURES TO PREVENT DEG/EG CONTAMINATION IN O
2025-04-21
Rapid Alert: CONTAMINATED PROPYLENE GLYCOL (BATCH # YFO1210911) PURPOTEDLY MANUFACTURED BY
2025-03-15
Rapid Alert: Presence of Unregistered Tramadol Formulations in the Market
2025-02-27
Rapid Alert: CONTAMINATED PROPYLENE GLYCOL (BATCH # A803S96G46) PURPOTEDLY MANUFACTURED BY
2025-02-25
Rapid Alert: Contaminated Propylene Glycol (Batch # YF01210911) Allegedly Manufactured by
2024-12-12
Rapid Alert: Contaminated Propylene Glycol (Batch# YF01230522)
2024-10-25
Rapid Alert: Drug Product; Falsified Froxime 100mg/5mL Powder for Oral Suspension
2024-05-28

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

NEUTRO PHARMA (PVT) LTD. holds 100 molecules not in this portfolio
AcetylcysteineAcyclovirAmikacinAnastrazoleAnastrozoleAntimony
GETZ PHARMA PAKISTAN (PVT) LTD. holds 233 molecules not in this portfolio
),Formoterol3 ) 20Mg} Folic AcidAcetazolamideAcyclovirAdrenalineAmitriptyline
BIO LABS (PVT) LTD. holds 110 molecules not in this portfolio
AprepitantAremetherArtesunateAtorvastatinAzathioprineAzithromycin 250Mg

Get the full profile for The

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.